Jie Wang

Jie Wang is Professor of Medical Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing. She led the RATIONALE-304 and RATIONALE-307 trials of tislelizumab, the PD-1 antibody from BeOne Medicines, formerly BeiGene, in non-small-cell lung cancer, and has been principal investigator on many other Chinese registrational lung cancer studies. These include EGFR tyrosine kinase inhibitor and ALK trials in non-small-cell lung cancer and studies of Chinese PD-1 antibodies in small-cell lung cancer. Her interests are lung cancer, immunotherapy, targeted therapy and clinical trials.